Renal Cell Carcinoma: Clinical Management provides a comprehensive, state-of-the art review of this field, and will serve as a valuable resource for clinicians, surgeons and researchers with an interest in kidney cancer. The volume reviews new data about risk factors for the disease, profiles the new staging system for renal cell carcinoma (RCC), highlights our current understanding of familial syndromes of RCC and their molecular genetics, and provides new perspectives about imaging of renal tumors. For localized disease, a greater appreciation of nephron-sparing approaches and the importance of preservation of renal function is discussed in detail. Advances in surgical techniques are highlighted. For metastatic disease, the molecular biology of kidney cancer is reviewed in a concise and understandable manner, including the data that has fostered novel targeted approaches that have revolutionized management. The several landmark phase III targeted therapy trials published in the last few years are placed in context with respect to current management. Integration of surgery and systemic therapy through cytoreductive and consolidative approaches has yielded provocative data that promises to further advance the field, and major advances in this domain are also be discussed.

In this issue of Urologic Clinics of North America, guest editors Drs. Michael L. Blute and Steven L. Chang bring their considerable expertise to the topic of Renal Cancer: Old and New Paradigms. Recent significant advances in the management of renal cancer have expanded beyond simply eliminating disease to preserving and optimizing quality of life. In this issue, top experts highlight historical perspectives as well as current status and future treatments of renal cancer. - Contains 13 practice-oriented topics on biomarkers for the detection and surveillance of renal cancer; the changing role of renal mass biopsy; renal cysts: an oncological conundrum; the surgical management of renal cancer with inferior vena caval thrombus; integrating surgery in the multidisciplinary care of advanced renal cancer; and more. - Provides in-depth clinical reviews on renal cancer, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

The Guest Editor has gathered top experts to present thorough coverage of the diagnosis and management of renal cortical tumors. The issue spans topics on lymphadenectomy, partial nephrectomy, molecular imaging, surgical management, and systemic therapy. Authors also discuss contemporary concerns in the management of renal tumors, pathological features, and epidemiology, clinical presentation, and clinical staging.

Renal Cell Carcinoma: Clinical Management provides a comprehensive, state-of-the art review of this field, and will serve as a valuable resource for clinicians, surgeons and researchers with an interest in kidney cancer. The volume reviews new data about risk factors for the disease, profiles the new staging system for renal cell carcinoma (RCC), highlights our current understanding of familial syndromes of RCC and their molecular genetics, and provides new perspectives about imaging of renal tumors. For localized disease, a greater appreciation of nephron-sparing approaches and the importance of preservation of renal function is discussed in detail. Advances in surgical techniques are highlighted. For metastatic disease, the molecular biology of kidney cancer is reviewed in a concise and understandable manner, including the data that has fostered novel targeted approaches that have revolutionized management. The several landmark phase III targeted therapy trials published in the last few years are placed in context with respect to current management. Integration of surgery and systemic therapy through cytoreductive and consolidative approaches has yielded provocative data that promises to further advance the field, and major advances in this domain are also be discussed.

From the basic science underpinnings to the most recent developments in medical and surgical care, Campbell-Walsh-Wein Urology offers a depth and breadth of coverage you won’t find in any other urology reference. Now in three manageable volumes, the revised 12th Edition is a must-have text for students, residents, and seasoned practitioners, with authoritative, up-to-date content in an intuitively organized, easy-to-read format featuring key points, quick-reference tables, and handy algorithms throughout. Features shorter, more practical chapters that help you find key information quickly. Includes new chapters on Urinary Tract Imaging: Basic Principles of Nuclear Medicine · Ethics and Informed Consent · Incisions and Access · Complications of Urologic Surgery · Urologic Considerations in Pregnancy · Intraoperative Consultation · Special Urologic Considerations in Transgender Individuals · and more. Covers hot topics such as minimally invasive and robotic surgery; advancements in urologic oncology, including innovative therapeutics for personalized medicine; new approaches to male infertility; technological advances for the treatment of stones; and advances in imaging modalities. Incorporates current AUA/EAU guidelines in each chapter as appropriate Updates all chapters with new content, new advances, and current references and best practices. Extensively updated chapters include Urological Immunotherapy, Minimally Invasive Urinary Diversion, and Updated Focal Therapy for Prostate Cancer. Features more than 175 video clips, including all-new videos on perineal ultrasound, abdominoplasty in prune belly syndrome, partial penectomy, low dose rate brachytherapy, and many more. Written and edited by key opinion leaders, reflecting essential changes and controversies in the field.

Despite the rising popularity of the minimally invasive laparoscopic option, open nephron-sparing surgery is still seen by many experts as the 'gold standard' for open surgery for kidney tumors and should remain the first choice for many patients. This challenges the idea that less-invasive therapies are always more desirable than open surgery. Whi